Relapsed pediatric high-grade glioma and high-risk neuroblastoma have poor outcomes for patients. In order to advance therapies for children with these tumors researchers must expand upon their genetic understanding with further research. The goal of the Center for Pediatric Tumor Cell Atlas (CPTCA) is to characterize molecular interactions at critical transition points in 3 deadly pediatric cancers: pediatric high grade glioma (pHGG), high risk neuroblastoma (HR NB) and very high-risk B-cell ALL (VHR ALL). Understanding how a tumor is molecularly changed at different transition points, such as in response to therapy and at the point of recurrence, could lead to advancements in care. In addition, the CPTCA’s historical commitment to both resource and data sharing guarantee that the entire research and patient community will benefit. The Children's Brain Tumor Network contributed to this project by providing samples, genomic data and imaging data of rare pediatric brain cancer specimens necessary to carry out this line of questioning.
What are the goals of this project?
Researchers will analyze tissue samples and genomic data in an effort to better understand how a tumor changes in response to therapeutics.
What is the impact of this project?
A greater understanding of how a tumor changes over time and in response to therapies could lead to advancements in personalized care.
Why is the CBTN request important to this project?
Researchers need both comprehensive data and rare specimens to carry out this work, all of which is provided by the Children’s Brain Tumor Network.
The Children's Brain Tumor Network contributed to this project by providing samples, genomic data and imaging data.
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test